ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.19
+0.12 (1.49%)
At close: Apr 23, 2026, 4:00 PM EDT
8.15
-0.04 (-0.49%)
After-hours: Apr 23, 2026, 7:59 PM EDT
ImmunityBio Revenue
In the year 2025, ImmunityBio had annual revenue of $113.29M with 668.31% growth. ImmunityBio had revenue of $38.29M in the quarter ending December 31, 2025, with 406.95% growth.
Revenue (ttm)
$113.29M
Revenue Growth
+668.31%
P/S Ratio
74.66
Revenue / Employee
$163,948
Employees
691
Market Cap
8.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 113.29M | 98.54M | 668.31% |
| Dec 31, 2024 | 14.75M | 14.12M | 2,270.58% |
| Dec 31, 2023 | 622.00K | 382.00K | 159.17% |
| Dec 31, 2022 | 240.00K | -694.00K | -74.30% |
| Dec 31, 2021 | 934.00K | 329.00K | 54.38% |
| Dec 31, 2020 | 605.00K | -1.60M | -72.52% |
| Dec 31, 2019 | 2.20M | 2.16M | 4,585.11% |
| Dec 31, 2018 | 47.00K | 2.00K | 4.44% |
| Dec 31, 2017 | 45.00K | 1,000.00 | 2.27% |
| Dec 31, 2016 | 44.00K | -192.00K | -81.36% |
| Dec 31, 2015 | 236.00K | -405.00K | -63.18% |
| Dec 31, 2014 | 641.00K | 41.00K | 6.83% |
| Dec 31, 2013 | 600.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.40B |
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 1.09B |
| Axsome Therapeutics | 638.50M |
| Krystal Biotech | 389.13M |
| Cytokinetics | 88.04M |
| Kymera Therapeutics | 39.21M |
| Praxis Precision Medicines | 7.46M |
IBRX News
- 13 hours ago - IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: SueWallSt - PRNewsWire
- 1 day ago - IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - GlobeNewsWire
- 2 days ago - IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline - Newsfile Corp
- 2 days ago - ImmunityBio Stock Rises As ANKTIVA Launches in Saudi Arabia - Benzinga
- 2 days ago - ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership - Business Wire
- 3 days ago - IBRX Stockholders Have Rights – If You Lost Money Investing in ImmunityBio, Inc. Contact Robbins LLP for Information About Recovering Your Losses - GlobeNewsWire
- 3 days ago - ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C. - GlobeNewsWire
- 7 days ago - IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt - PRNewsWire